A successful clinical trial published in a major scientific journal will show psilocybin helps people quit cocaine. This result will prompt at least two pharmaceutical companies (like COMPASS Pathways or ATAI Life Sciences) to file new Investigational New Drug applications (INDs — official permission to run human trials) or expand their existing trials. This matters because it opens a new market for psychedelic treatments beyond depression and anxiety.
A peer-reviewed RCT in a major journal is a standard IND-triggering event. COMPASS Pathways and ATAI Life Sciences both have IND infrastructure and stated interest in expanding indications. However, 'two new INDs' is a high bar: IND preparation typically takes 6–12 months from data availability, cocaine use disorder has a historically difficult regulatory path, and 'major trial amendment' is ambiguous enough to be nearly unfalsifiable. Tightened to require either new IND filings or amendments that add cocaine use disorder as a primary endpoint — not protocol administrative changes. Confidence moderately reduced from single-agent score given 7-month window and organizational inertia.